[Edaily Reporter NA EUN-KYUNG ] Medical artificial intelligence (AI) company Coreline Soft Co., Ltd.(384470)is expanding its chest computed tomography (CT)-based multi-disease analysis business in Japan. Following the recent approval of its proprietary lung nodule diagnostic assistance solution, “AVIEW Lung Nodule CAD,” by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), the company is expanding its product portfolio by beginning to supply its coronary artery calcification (CAC) analysis solution, “AVIEW CAC.”

Coreline Soft Co., Ltd. announced on the 30th that it has signed a supply agreement with Japan’s M3 AI for “AVIEW CAC.” AVIEW CAC is an AI solution that automatically detects and quantifies coronary artery calcification (CAC) in chest CT images, providing information necessary for assessing the risk of cardiovascular disease.

A key feature is its ability to analyze coronary artery calcification in addition to the original purpose—such as diagnosing lung diseases—of previously acquired chest CT scans. This approach, known as “opportunistic screening,” involves identifying other diseases or risk factors in images originally acquired for a specific condition. Through this, Coreline Soft Co., Ltd. plans to expand its “One CT, Multi-Disease” strategy, which analyzes both lung disease and cardiovascular risk from a single chest CT scan.

Japan is a market with a significant burden of cardiovascular disease linked to CAC analysis. According to the 2024 Vital Statistics report from Japan’s Ministry of Health, Labor and Welfare, deaths from heart disease (excluding hypertensive disorders) totaled 226,388, accounting for 14.1% of all deaths and ranking as the second leading cause of death after cancer.

The country also has a well-established medical imaging infrastructure. According to the Organization for Economic Cooperation and Development (OECD), Japan’s CT scanner density—at over 115 units per 1 million people—is the highest among the countries surveyed. This indicates that the market environment is ripe for adding AI analysis capabilities to CT images already generated in clinical settings, rather than building new imaging infrastructure.

Coreline Soft Co., Ltd. acquired assets related to “VUNO Med-LungCT” last year, securing a customer base and distribution network in Japan, and has since expanded its client base to approximately 80 hospitals. Following the recent PMDA approval for its proprietary lung nodule CAD, the company is expanding its Japanese business from a focus on lung nodules to a product portfolio for the analysis of multiple thoracic CT conditions by adding “eView CAC.”

Kim Jin-guk, CEO of Coreline Soft Co., Ltd., stated, “Following the recent PMDA approval in Japan for our pulmonary nodule diagnostic aid solution—which secured the regulatory foundation for our proprietary products—we are now expanding our Japanese business portfolio to include eView CAC.” He added, “As Japan is a market with one of the highest levels of CT utilization globally, we plan to gradually expand our strategy of providing a wide range of clinical information—including not only pulmonary diseases but also cardiovascular risks—from a single chest CT scan.”